Oxford Biomedica to Regain Rights to RetinoStat
April 29 2014 - 5:32AM
Dow Jones News
LONDON--Oxford Biomedica PLC (OXB.LN), a biopharmaceutical
company, Tuesday said it will regain the worldwide rights to
RetinoStat, a macular degeneration treatment, after Sanofi (SNY)
decided not to develop it beyond a Phase I study.
MAIN FACTS:
-Sanofi has confirmed that this decision is not linked to
unexpected results based on an analysis of the data from the study.
.
-Indicative results from study seen towards end-2014
-Shares in Oxford Biomedica down 12.5% at 0857 GMT
-Write to Ed Ballard at ed.ballard@wsj.com; Twitter:
@edmballard
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024